A prospective, observational study assessing efficacy of Netupitant/palonosetron, without dexamethasone, in preventing Chemotherapy-induced nausea and vomiting
Latest Information Update: 31 Dec 2021
At a glance
- Drugs Netupitant/palonosetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 31 Dec 2021 New trial record
- 27 Dec 2021 Primary endpoint has been met (Rate of complete response (no emesis and no rescue medication) (CR) at 120 h after conditioning) according to the results published in the Supportive Care in Cancer
- 27 Dec 2021 Results published in the Supportive Care in Cancer